Zhong Huijuan

New Capabilities

As of September 2026: Steering Hansoh's pivot from generics to innovative oncology

On September 2, 2026, China's drug regulator accepted the first marketing application for Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around the protein B7-H3. The filing covers small cell lung cancer after prior platinum-based chemotherapy and follows a July phase 3 win: the ARTEMIS-008 trial met its primary endpoint of overall survival, making HS-20093 the first B7-H3-directed antibody-drug conjugate to show a survival benefit in any tumor type.

Updated Sep 13